SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Senior who wrote (75854)2/25/2025 10:04:01 AM
From: E_K_S  Read Replies (1) of 78517
 
RE: Solventum Corporation (SOLV) 82.67 +6.39 (+8.38%)

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Solventum Corporation (NYSE: SOLV) is a healthcare company that was spun off from 3M on April 1, 2024. Debt and Financial Situation At the time of the spin-off, Solventum was saddled with a significant debt load: Long-term debt of $8.3 billion The company prioritized debt paydown for approximately 24 months following the spin-off This debt burden has limited Solventum's ability to return capital to shareholders or pursue acquisition
Top Divisions: Solventum's business segments include:
  1. Medical Equipment (MedSurg): The largest segment, accounting for over half of the company's $8.2 billion sales in 2023 5

  2. Purification and Filtration

  3. Dental Care Equipment (Dental Solutions)

  4. Healthcare Industry Software (Health Information Systems)
---------------------------------------------------------------------------------

Selling their Purification & Filtration Business and use those proceeds to pay down debt, should help them grow their other divisions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext